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a  b  s  t  r  a  c  t
Objective: To describe the clinical and laboratory features of children and adolescents with
acute lymphoblastic leukemia treated at three referral centers in Ceará and evaluate
prognostic factors for survival, including age, gender, presenting white blood cell count,
immunophenotype, DNA index and early response to treatment.
Methods: Seventy-six under 19-year-old patients with newly diagnosed acute lymphoblastic
leukemia treated with the Grupo Brasileiro de Tratamento de Leucemia da Infância – acute
lymphoblastic leukemia-93 and -99 protocols between September 2007 and December 2009
were analyzed. The diagnosis was based on cytological, immunophenotypic and cytoge-
netic  criteria. Associations between variables, prognostic factors and response to treatment
were analyzed using the chi-square test and Fisher’s exact test. Overall and event-free sur-
vival  were estimated by Kaplan–Meier analysis and compared using the log-rank test. A Cox
proportional hazards model was used to identify independent prognostic factors.
Results: The average age at diagnosis was 6.3 ± 0.5 years and males were predominant (65%).
The most frequently observed clinical features were hepatomegaly, splenomegaly and lym-
phadenopathy. Central nervous system involvement and mediastinal enlargement occurred
in  6.6% and 11.8%, respectively. B-acute lymphoblastic leukemia was more common (89.5%)
than T-acute lymphoblastic leukemia. A DNA index >1.16 was found in 19% of patients and
was  associated with favorable prognosis. On Day 8 of induction therapy, 95% of the patients
had lymphoblast counts <1000/L and white blood cell counts <5.0 × 109/L. The remission
induction rate was 95%, the induction mortality rate was 2.6% and overall survival was 72%.
Conclusion: The prognostic factors identiﬁed are compatible with the literature. The 5-year
overall and event-free survival rates were lower than those reported for developed coun-
tries.  As shown by the multivariate analysis, age and baseline white blood cell count were
independent prognostic factors.©  2015 Associac¸ão Bra
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
malignancy in children and represents 75–80% of acute
leukemia in this age group. The incidence of childhood ALL
is 3–4 cases per 100,000 in under 15-year-old children. Despite
affecting children of all ages, the incidence peaks between two
and ﬁve years of age, with a slight predominance among boys.1
ALL is a heterogeneous disease; subtypes differ with regard
to biological, cellular and molecular characteristics, response
to therapy and risk of relapse, and are associated with different
outcomes.2
The survival rate of pediatric ALL patients has improved to
approximately 90% in recent years, especially for groups with
good prognosis. This progress is mainly due to the adoption of
modiﬁcations in therapy based on patients’ individual phar-
macodynamics and pharmacogenomics, risk-adapted therapy
and improved supportive care.2,3
Stratiﬁcation into risk groups is based on a range of clini-
cal, biological and genetic features, such as age and gender,
white blood cell (WBC) count at diagnosis, immunopheno-
typic, cytogenetic and molecular characteristics, and early
medullar response to induction therapy.4–6 Early response to
therapy determined by the level of minimal residual disease
(MRD) at the end of induction is currently the most important
prognostic factor in patients with ALL.7
The identiﬁcation of prognostic factors, an improved strat-
iﬁcation of risk groups and survival analysis have made it
possible to identify presenting features of the disease and
evaluate treatment outcome in referral centers in Ceará,
thereby contributing to current knowledge of the epidemiol-
ogy of pediatric malignancies, both locally and throughout all
Brazil.
The purpose of this study was to describe the clinical
and laboratory features of children and adolescents with ALL
treated at three referral centers in the state of Ceará, Brazil and
evaluate prognostic factors for survival, including age, gender,
presenting WBC  count, immunophenotype, DNA index and
early response to treatment.
Methods
This prospective study was based on a sample of 76 under
19-year-old patients with newly  diagnosed ALL treated with
the Grupo Brasileiro de Tratamento de Leucemia da Infân-
cia – acute lymphoblastic leukemia (GBTLI-ALL)-93 protocol
(n = 64) or the GBTLI-ALL-99 protocol (n = 12) between Septem-
ber 2007 and December 2009. Patients were treated at the
pediatric oncology services of Hospital Infantil Albert Sabin
(HIAS), Hospital do Câncer Haroldo Juac¸aba (HC) and Hospital
Luis Franc¸a (HLF). HIAS and HC are public referral hospitals
providing treatment of childhood cancer in Ceará. All par-
ents and/or patients gave their written informed consent. The
study was approved by the Research Ethics Committees of HC
(Protocol 66/2007) and HIAS (Protocol 058/08).
The observed clinical variables included age at diagno-
sis, gender, hepatomegaly, splenomegaly, lymphadenopathy,
mediastinal mass, inﬁltration of the central nervous system 2 0 1 5;3  7(4):223–229
(CNS), WBC  count, hemoglobin and lactate dehydrogenase
(LDH) levels, platelet count, immunophenotype and DNA
Index (DI).
Treatment response was evaluated based on the present-
ing WBC  count, the lymphoblast count on the eighth day of
induction therapy (Day 8), and bone marrow (BM) analysis on
Day 28 of induction.
ALL was diagnosed in patients with ≥25% lymphoblasts in
BM (based on morphological and cytochemical evaluations of
BM smears) and positivity in immunophenotyping and cytoge-
netics. The DI was determined by ﬂow cytometry. Peripheral
blood, bone marrow and cerebrospinal ﬂuid (CSF) were col-
lected at referral hospitals.
CNS involvement was diagnosed in patients with >5
WBC/L in CSF and lymphoblasts identiﬁed on the cytocen-
trifuge slide.
According to the GBTLI risk criteria, risk of relapse (low vs.
high) was stratiﬁed based on age, WBC  count at diagnosis and
early response to therapy. The following pretreatment char-
acteristics were observed in high-risk patients: age less than
one, age greater than nine, WBC  >50.0 × 109 cells/L, and lym-
phoblast count >1000 cells/L or WBC  count >5.0 × 109 cells/L
on Day 8. All other patients were classiﬁed as low risk of
relapse.8,9
Statistical  analysis
The statistical analysis was carried out using the R statis-
tical language version 2.1.10 Descriptive statistics were used
to characterize the patients. Associations between variables,
prognostic factors and response were analyzed with the chi-
square test and Fisher’s exact test. Five-year overall survival
(OS) and event-free survival (EFS) rates were estimated with
the Kaplan–Meier method and compared with the log-rank
test. The Cox proportional hazards model11 was used to iden-
tify independent prognostic factors with respect to EFS and
OS. The level of statistical signiﬁcance was set at 5% (p-value
<0.05).
Results
The clinical and laboratory features at diagnosis for this sam-
ple of 76 patients are summarized in Tables 1 and 2. Low and
high risk of relapse was attributed to 54% (n = 41) and 46%
(n = 35) of the sample, respectively.
The average age at diagnosis was 6.3 ± 0.5 years
(median = 5.3). Males (65.8%) were predominant in the
sample (male/female ratio = 1.9:1).
The most prevalent age group was one to nine years (75%).
Under one-year-old and over nine-year-old patients accounted
for 2.6% and 22.4%, respectively. Age less than one was associ-
ated with unfavorable prognostic factors, such as presenting a
high baseline WBC  count, pro-B immunophenotype and CD10
negativity. Age between one and nine years was associated
with more  favorable prognostic factors, such as a WBC  count
<50.0 × 109 cells/L, CD10 positivity and DI >1.16.
The most frequent clinical features were hepatomegaly,
splenomegaly, fever and lymphadenopathy. CNS involvement
rev bras hematol hemoter. 2 0
Table 1 – Presenting clinical and biological
characteristics of 76 children and adolescents with acute
lymphoblastic leukemia (B-ALL and T-ALL) treated at
three referral centers in Ceará, Brazil, between
September 2007 and December 2009.
Overall (n = 76) B-ALL (n = 68) T-ALL (n = 8)
Age (years)
<1 2 (2.6) 2 (2.94) –
≥1 < 9 57 (75) 54 (79.4) 3 (37.5)
≥9 17 (22.4) 12 (17.6) 5 (62.5)
Gender
Male 50 (65.8) 44 (64.7) 6 (75)
Female 26 (34.2) 24 (35.3) 2 (25)
Risk group
High 35 (46) 28 (41.2) 7 (87.5)
Low 41 (54) 40 (58.8) 1 (12.5)
FAB
L1 63 (83) 56 (82.4) 7 (87.5)
L2 13 (17) 12 (17.6) 1 (12.5)
Extramedullary invasion
Hepatomegaly 48 (63) 43 (63.2) 5 (62.5)
Splenomegaly 44 (57.8) 40 (58.8) 4 (50)
Lymphadenopathy 33 (43.4) 26 (38.2) 7 (87.5)
CNS disease 5 (6.5) 4 (5.9) 1 (12.5)
Mediastinal mass 9 (11.8) 3 (4.4) 6 (75)
Values are expressed in absolute numbers of patients with certain
characteristics (percentage relative to the total number of patients
















WBC  count and lymphoblast count on Day 8 remained statis-CNS: central nervous system.
nd mediastinal mass were observed in 6.6% and 11.8%,
espectively.
Anemia was diagnosed in 85% of the patients, 35% of whom
ad severe anemia (Hb < 7 g/dL); the mean hemoglobin level
as 8.24 g/dL. At diagnosis, patients with T-ALL presented
igniﬁcantly higher Hb levels (10.6 ± 2.45 g/dL) than patients
ith B-ALL (7.9 ± 2.55 g/dL; p-value = 0.011). A platelet count
100.0 × 109 cells/L was observed in 65%, and 10.5% had severe
hrombocytopenia with platelet counts <20.0 × 109 cells/L. The
verage WBC  count at diagnosis was 31.8 ± 53.4 × 109 cells/L
range: 0.9–320.0 × 109 cells/L). Sixteen patients (21%) were
lassiﬁed as high risk of relapse (WBC count >50.0 × 109 cells/L)
Table 2). In 4%, the peripheral blood cell count was nor-
al  at diagnosis, with no changes in hemoglobin level, WBC
r platelet counts and no lymphoblasts in peripheral blood
mears.
Table 2 – Baseline laboratory characteristics of 76 children and 
and T-ALL) treated at three referral centers in Ceará, Brazil, betw
Overall (n = 76) 
Hemoglobin (g/dL) 8.24 ± 2.68 
WBC × 109 cells/L 31.77 ± 53.35 
Platelets × 109 cells/L 109.80 ± 122.92 
LDH level (U/L) 1506.43 ± 1194.03 
CD10 positivity n (%) 72 (95) 
Levels expressed as mean values ± standard error of the mean (SEM).
WBC: white blood cells; LDH: lactate dehydrogenase. 1 5;3  7(4):223–229 225
LDH >1000 U/L was used as a prognostic marker (nor-
mal: 480 U/L). Thus, 39 patients (51.3%) presented LDH levels
>1000 U/L (mean: 1506.43 ± 1194.03 U/L) (Table 2).
B immunophenotype ALL was identiﬁed in 89.5%. The most
prevalent subtypes were common B-ALL (51.5%) and pre-B
(45.5%). Pro-B was found in about 3% of cases. Patients with
mature B or French-American-British (FAB) classiﬁcation of L3
were not included in this study.
T immunophenotype ALL was found in 10.5%. The most
prevalent European Group for the Immunological Character-
ization of Leukemias (EGIL) subtypes were pre-T (50%) and
cortical T (37.5%). T-ALL was associated with unfavorable fac-
tors including the following: being male, over nine years in
age, leukocytosis, CD10 negativity, mediastinal mass, and CNS
involvement (Table 1).
DI was determined by ﬂow cytometry in 58 patients.
Overall, 76% were diploid (DI = 1) and 24% were hyper-
diploid (DI > 1.0). Observed in 19%, DI >1.16 was associated
with low risk of relapse and favorable factors such as age
between one and nine years, WBC  count <20.0 × 109 cells/L (p-
value = 0.028), B immunophenotype, and 100% CD10 positivity
(Table 3). These patients responded well to induction ther-
apy (on Day 8, lymphoblast count <1000/L and WBC  count
<5.0 × 109 cells/L), with complete hematological remission and
absence of early relapse. Outcome according to DI showed that
patients with DI >1.16 fared better (5-year EFS: 100%) than
patients with DI <1.16 (5-year EFS: 66%; p-value = 0.03).
The median follow-up was 60 months. Seventy-two
patients (95%) achieved complete remission. On Day 8, 95%
of the patients had a lymphoblast count <1000/L and WBC
count <5.0 × 109 cells/L. Twelve (16%) patients relapsed and
two (2.6%) died during induction.
EFS for all 76 patients was 71.2 ± 5.2% [95% conﬁdence inter-
val (95% CI): 62.1–82.8%] and 5-year OS was 72 ± 5.24% (95% CI:
62–82%), with higher EFS rates in the low-risk group (83%; 95%
CI: 72–95%) and in patients with B-ALL (73%; 95% CI: 63–85%)
(Figure 1A and B).
Age at diagnosis and presenting WBC  count were statis-
tically signiﬁcant prognostic factors. The highest EFS rates
were observed in children aged one to nine years (73%;
95% CI: 63–85%) and in patients with presenting WBC  count
<50.0 × 109 cells/L (73%; 95% CI: 63–85%) (Figure 1C and D).
In the multivariate analysis, age at diagnosis, presentingtically signiﬁcant with regard to risk of relapse after adjusting
for gender, risk group, CD10 expression, and early response to
therapy (Table 3).
adolescents with acute lymphoblastic leukemia (B-ALL
een September 2007 and December 2009.
B-ALL (n = 68) T-ALL (n = 8)
7.9 ± 2.55 10.8 ± 2.45
24.30 ± 4.80 95.25 ± 36.31
109.97 ± 123.16 108.38 ± 129.34
1458.50 ± 140.5 1913.88 ± 524.17
66 (97.1) 2 (25)
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Table 3 – Characteristics according to DNA ploidy of 76
children and adolescents with acute lymphoblastic
leukemia treated at three referral centers in Ceará,
Brazil, between September 2007 and December 2009.
DI < 1.16
(n = 47)
DI  > 1.16
(n = 11)
p-value
Age – n (%)
1 < 5 years 24 (51) 7 (63.6) 0.309
5 < 9 years 14 (30) 4 (36.4)
≥9 years 9 (19) –
Risk group – n (%)
Low 25 (53.2) 10 (91) 0.037
High 22 (46.8) 1 (9.0)
Immunophenotype – n (%)
B 44 (93.6) 11 (100) 1.000
T 3 (54) –
Initial WBC count – n (%)
<20.0 × 109 cells/L 27 (57.5) 11 (100) 0.028
>20.0–50.0 × 109 cells/L 8 (17) –
>50.0 × 109 cells/L 12 (25.5) –
CD10 – n (%)
Positive 42 (89.4) 11 (100) 0.572
Negative 5 (10.6) –
Values are expressed in absolute numbers of patients with certain
characteristics (percentage relative to the total number of patients
in their subgroup in parentheses).
increased risk of induction failure, early relapse and isolatedDI: DNA Index.
The comparison of relative risk revealed that the risk was
higher for patients with WBC  counts >50.0 × 109 cells/L at diag-
nosis (HR = 589; 95% CI: 7–4757). The wide range of the CI is due
to the relatively small number of patients with elevated WBC
counts (n = 16). The other prognostic factors (age and number
of lymphoblasts on Day 8) had a relative risk between 0.2 and
1.0, with a wide variation of 95% CI, indicating a weaker inﬂu-
ence on OS. The same prognostic factors were associated with
EFS, with relative risks of the same magnitude.
Discussion
Little has been published on the epidemiology of childhood
and juvenile ALL in Northeastern Brazil. The present study
looks into the epidemiological and clinical aspects, prognostic
factors and response to therapy of children with ALL treated
at referral centers in the state of Ceará.
The age of our patients was signiﬁcantly correlated with
prognosis. Thus, under 1-year-old infants and patients older
than nine presented poorer prognoses. Infancy was associated
with unfavorable prognostic factors such as high presenting
WBC  count, Pro-B immunophenotype, CD10 negativity, hep-
atosplenomegaly and poor response to induction treatment,
thus matching ﬁndings in the literature.12
Over nine-year old children and adolescents accounted for
22.4% of the cases in this study. Historically, adolescents and
young adults have higher relapse rates and shorter survival
than children aged one to nine years. The worse outcomes
in this group may be due to the high prevalence of bio-
logically high-risk leukemia (e.g. breakpoint cluster region 2 0 1 5;3  7(4):223–229
protein-Abelson murine leukemia viral oncogene homolog
1 [BCR-ABL1] and mixed-lineage leukemia [MLL] rearrange-
ments) in association with unfavorable factors such as high
WBC  count, T-cell immunophenotype, and poor adherence to
and tolerance of therapy.13,14
Recent studies have shown that adolescents and young
adults have better outcomes and higher rates of continuous
remission when treated according to pediatric protocols with
higher doses of non-myelosuppressive drugs, rather than with
adult regimens.14,15
Males were predominant in the present study matching
the ﬁndings of Brazilian studies from Bahia,16 Pernambuco,17
and Rio Grande do Sul,18 and the GBTLI-ALL-99 protocol.19
In two studies, males with low EFS rates had unfavorable
prognoses.19,20
Hepatomegaly, splenomegaly and lymphadenopathy, fever
and severe anemia were the most frequently observed clini-
cal features in this study as in other published reports.1 CNS
involvement occurred in 6.6% of the patients. This is consis-
tent with the rate (6.7%) reported in Bahia,16 and elsewhere
in the world (0.6–12.4%).21 The GBTLI-ALL 93 protocol and
the GBTLI-ALL 99 protocol yielded lower rates (1.7% and 2.4%,
respectively).8,9
Anemia occurred in 85% of the patients in the current study,
most of whom were normochromic and normocytic. Severe
anemia (Hb <7 g/dL) was observed in 35%. Patients with T-
ALL presented signiﬁcantly higher Hb levels at diagnosis than
patients with B-ALL (mean Hb level, 10.6 g/dL vs. 7.9 g/dL).
According to some authors, lower Hb levels at diagnosis are
associated with more  advanced disease.22
Platelet counts <20.0 × 109 cells/L were found in 10.5%.
Despite the increased risk of bleeding; no severe bleeding was
observed in our sample.
WBC  count at diagnosis >50.0 × 109 cells/L was registered
in 21% of the patients, matching international studies that
report WBC  counts >50.0 × 109 cells/L in approximately 20%
of cases.21 Patients with severe leukocytosis at diagnosis
may present bulky tumor mass, mediastinal enlargement,
hepatosplenomegaly and signiﬁcant lymphadenopathy. This
ﬁnding is usually associated with the unfavorable chromoso-
mal  translocations t(4;11) and t(9;22).
T-ALL was observed in 10.5%. This incidence is slightly
lower than those of the GBTLI-ALL 93 and GBTLI-ALL 99 proto-
cols (13% and 14.2%, respectively)8,9 but consistent with other
national and international studies (7.4–16.4%).21,23
In this study, patients with T-ALL were more  likely to
present unfavorable factors such as being male, age greater
than nine years, high WBC  count at diagnosis, low CD10
expression, mediastinal enlargement and CNS involvement
(Tables 1 and 2). These results are compatible with those
reported by Goldberg et al. 23
Historically, the T-cell immunophenotype has been con-
sidered an adverse clinical prognostic factor in childhood
ALL, although its effect has been reduced by contemporary
risk-adapted therapy and improved supportive care.23 Nev-
ertheless, patients with this immunophenotype are still atCNS relapse.
In the present study, DI >1.16 was associated with a favor-
able prognosis (Table 3). In fact, at the end of induction, all
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Figure 1 – Kaplan–Meyer estimate of overall survival (OS) and event-free survival (EFS) of children and adolescents with
acute lymphoblastic leukemia. A – OS in Black and EFS in gray, with 95% conﬁdence interval; B – OS according to risk group
(low and high risk); C – OS according to age at diagnosis less than or greater than nine years old); D – OS based on white






















eigniﬁcance in the multivariate analysis: *p-value <0.05; **p-
atients with DI >1.16 were alive and were in complete remis-
ion with no early recurrence. These ﬁndings are compatible
ith the results of Aricó et al.24 and Dastugue et al.,25 who
ound a strong association between hyperdiploidy and favor-
ble prognostic factors such as age between one and ﬁve years
nd WBC  count at diagnosis <20.0 × 109 cells/L.
In one study,24 the OS was 95–96% and EFS was 89% in
atients with DI ≥1.16 (corresponding to 53 chromosomes).
ore  recent investigations have shown that patients with
-ALL hyperdiploidy (58–66 chromosomes) are almost com-
letely curable.25 In contrast, hypodiploid patients with fewer
han 45 chromosomes (no more  than 2% of cases) have a poor
rognosis.
Early response to treatment was deﬁned as a reduction
n peripheral WBCs and circulating lymphoblasts on Day 8
nd early bone marrow response at the end of induction (Day
8).26,27
On Day 8, 5% of our patients had lymphoblast counts
1000 cells/L and WBC  counts >5.0 × 109 cells/L. Deﬁned as
oor responders, these patients were associated with signif-
cantly lower EFS rates. Poor responders also displayed lower
FS rates (∼45–52%) in the GBTLI-ALL-99 protocol.9 According
o Manabe et al., patients with no lymphoblasts in the periph-
ral blood on Day 8 had an excellent outcome, with over 90%e <0.01.
surviving at four years.28 A recent study by Vaghela et al. sup-
ports the prognostic value of peripheral lymphoblast counts
on Day 8 of induction therapy.29
At the end of induction, 95% of the patients in the cur-
rent study had achieved remission. This is in agreement with
Brazilian and international studies that show a continuous
remission rate of 95–99%.9,20 In this study, the bone marrow
evaluation on Day 28 was performed only by morphological
analysis, although many  authors have stressed the signiﬁ-
cance of response to remission induction therapy expressed
by minimal residual disease (MRD).7 In 30% of patients treated
according to the Brazilian GBTLI LLA-99 study, the presence of
MRD  on Day 28 of induction was the independent prognostic
factor with the greatest impact in multivariate analysis, when
the EFS was analyzed in relation to the age and WBC  count at
diagnosis.9
In the GBTLI-ALL-2009 study, MRD  was used to identify
high-risk patients and use of intensive induction therapy. The
allocation of these patients according to “molecular response”
to treatment and early intensiﬁcation of therapy may improve
the outcome in childhood ALL in the state of Ceará and Brazil.Death during induction therapy occurred in 2.6% of the
cases in this study. This is similar to the results of the GBTLI-
ALL-93 protocol (3%), but higher than the rates reported for
228  rev bras hematol hemoter.
Table 4 – Results of the Cox proportional hazards model
of prognostic factors of acute lymphoblastic leukemia for
a sample of 76 children and adolescents treated at three
referral centers in Ceará, Brazil, between September
2007 and December 2009.
Variables Coefﬁcient SEM p-value
Age (≥9 years) 2.31 2.340 0.019
Risk group 1.18 1.004 0.320
Initial WBC count 6.04 2.644 0.008
CD10 (Calla) 2.75 1.767 0.070
WBC >5.0 × 109 cells/L (Day 8) 0.76 0.761 0.450
Lymphoblasts >1000 cells/L (Day 8) 4.01 2.159 0.030






1SEM: standard error of the mean; WBC: white blood cell count.
developed countries (0.5–1.4%),21,23 suggesting the induction
mortality rate is short of satisfactory at Brazilian centers. In
this study, infection was the most common cause of death.
At ﬁve years, the OS and EFS in the current sample were
72% and 71.2%, respectively. As expected, the survival rate
was higher for low-risk patients (83%) than for high-risk
patients (59%; Figure 1A and B). The corresponding ﬁgures
were 70% ± 3.6% and 69% ± 2.4% for the GBTLI-ALL-93 protocol
and 74.2 ± 1.7% and 68 ± 1.8% for the GBTLI-ALL-99 protocol,
with a signiﬁcant difference in favor of low-risk patients.8,9
Our ﬁgures are slightly better than those of Leite et al.17 and
Pereira,18 but not as good as the ﬁgures currently reported by
American and European collaborative childhood cancer treat-
ment groups.21,23
The OS and EFS were better for B-ALL patients, though the
difference was not statistically signiﬁcant. This ﬁnding differs
from the GBTLI-ALL-93 protocol in which the EFS at six years
was signiﬁcantly lower for T-ALL patients.8 This disagreement
might be attributed to the small number of T-ALL patients
in our study; however, in a study published by the Dana-
Farber group, differences in survival between T-ALL and B-ALL
(78% ± 4% vs. 86% ± 1%) were not signiﬁcant either, despite the
ﬁnding of increased risk of induction failure and relapse.23
In the current study, the OS was signiﬁcantly better for
under nine-year-old patients and patients with WBC  count at
diagnosis <50.0 × 109 cells/L (Figure 1C and 1D), as documented
in several other studies.8,9,21,23
In the multivariate analysis (Table 4), WBC  count at diag-
nosis >50.0 × 109 cells/L, age greater than nine years and high
peripheral lymphoblast counts (>1000 cells/L) on Day 8 were
signiﬁcantly associated with poor survival. No other prognos-
tic factors (FAB classiﬁcation, CD10 expression or DI) were
signiﬁcant.
Overall, the clinical and laboratory features observed in this
study are compatible with the results reported in the GBTLI-
ALL 93 and 99 protocols and elsewhere in the literature. The
multivariate analysis indicated that age, initial WBC  count and
early response to treatment were independent prognostic fac-
tors, whereas gender, FAB classiﬁcation, CD10 expression and
DI were not.
The estimated survival rates found were inferior to the
results obtained in developed countries. The 5-year EFS rate
was lower than that reported in the literature. However, low-
risk patients had a better prognosis. 2 0 1 5;3  7(4):223–229
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